We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Michael Nauck

Michael Nauck MD

Head of Clinical Research, Diabetes Center Bochum-Hattingen, St. Josef Hospital, Ruhr-University Bochum, Bochum, Germany

Michael Nauck is Head of Clinical Research at the Diabetes Division of St. Josef-Hospital (Ruhr-University Bochum) in Bochum, Germany. He teaches at Georg-August University, Göttingen, and Ruhr-University, Bochum, both in Germany. 

Professor Nauck has a particular research interest in the role of gastrointestinal peptide hormones (incretins: glucose-dependent insulinotropic polypeptide, GIP, and glucagon-like peptide-1, GLP-1) in the physiological regulation of metabolism and in the pathophysiology of type 2 diabetes. He has contributed pivotal studies proving a therapeutic potential of GLP-1 in type 2 diabetes. He has contributed to the development of incretin-based glucose-lowering medications such as GLP-1 receptor agonists and inhibitors of dipeptidyl peptidase-4. Additional areas of interest include spontaneous hypoglycaemia (insulinomas), pancreas transplantation, cardiovascular complications of type 2 diabetes, and the modification of cardiovascular risk in type 2-diabetic patients with glucose-lowering pharmacotherapy. His scientific contributions have been honoured with several awards, including the Ferdinand-Bertram Award (1993), the Werner-Creutzfeldt Award (2007) and the Paul Langerhans Medal (2012) of the German Diabetes Association.

Professor Nauck is member of a number of professional societies, including the German, European, American Diabetes Associations, and the International Diabetes Federation. He has served as reviewer for all major diabetes journals and has published more than 200 original articles and 145 reviews and book chapters.

Disclosures

Dr, Nauck has been member on advisory boards or has consulted with AstraZeneca, Eli Lilly & Co., Fractyl, GlaxoSmithKline, Menarini/Berlin Chemie, Merck, Sharp & Dohme, and NovoNordisk. He has received grant support from Eli Lilly & Co., Menarini/Berlin-Chemie, Merck, Sharp & Dohme, and Novartis Pharma. He has also served on the speakers bureau of AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., GlaxoSmithKline, Menarini/Berlin Chemie, Merck, Sharp & Dohme, NovoNordisk, and Sun Pharma.